Amryt Pharmaceuticals
Wednesday, 20 April 2016
Acted for Amryt Pharmaceuticals Designated Activity Company (Amryt DAC) in connection with the successful reverse takeover of Fastnet Equity plc, which has been renamed Amryt Pharma plc (Amryt). The enlarged share capital of Amryt has been admitted to trading today (19 April 2016) on AIM and ESM. As part of this transaction we also acted for Amryt DAC in connection with the acquisition of Birken AG and on certain matters relating to the acquisition of SomPharmaceuticals SA and SomTherapeutics Inc.
As part of this transaction Amryt has raised £10 million and the new funds will enable Amryt to accelerate the development of Episalvan® as a treatment for epidermolysis bullosa, a rare, debilitating, genetic skin disorder and orphan condition that typically affects young children and for which there is currently no approved therapy.
For further information on this transaction, visit www.amrytpharma.com
The ByrneWallace team who advised on this transaction included Colin Sainsbury (Partner and Head of Life Sciences Group), Catherine Dowling (Senior Associate) and Laura Greene (Solicitor).
